Pfizer Aromasin Cleared For Early Breast Cancer
This article was originally published in The Pink Sheet Daily
Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy
You may also be interested in...
Femara would be first breast cancer drug with adjuvant and extended adjuvant approvals, Novartis says. Supplemental NDA is based on a reduction of the risk of recurrence in the BIG 1-98 trial; the 8,000-patient study is continuing to determine if monotherapy or sequential therapy with tamoxifen is more effective.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.